Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients - Concepedia

Concepedia

Publication | Open Access

Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients

DOI Full Paper Access

64

Citations

24

References

2014

Year

Nicholas A. Kennedy, Rahul Kalla, Ben Warner, C. J. Gambles, R. Musy, Spencer Reynolds, Rakesh Dattani, H. Nayee, Richard Felwick, Richard Harris,

Alimentary Pharmacology & Therapeutics

Abstract

Thiopurine withdrawal in the context of sustained remission is associated with a 1-year moderate-to-severe relapse rate of 23% in Crohn's disease and 12% in ulcerative colitis.

References

	Year	Citations
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study Laurent Beaugerie, Nicole Brousse, Anne‐Marie Bouvier, The Lancet Lymphoproliferative DisordersGastroenterologyPathologyClinical GastroenterologyUlcerative Colitis	2009	1.1K
Treatment of Crohn's Disease with 6-Mercaptopurine Daniel H. Present, Burton I. Korelitz, Nathaniel Wisch, New England Journal of Medicine Ill PatientsUseful AgentPharmacologyGastroenterologyTherapeutic Controversy	1980	1K
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease Geert D’Haens, Marc Ferrante, Séverine Vermeire, Inflammatory Bowel Diseases	2012	797
A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease James Markowitz, Kathy Grancher, Nina Kohn, Gastroenterology GastroenterologyPediatricsPediatric GastroenterologyClinical GastroenterologyMulticenter Trial	2000	725
The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review Alan G. Fraser Gut	2002	626
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy Jean‐Frédéric Colombel, Nicolas Ferrari, Hervé Debuysère, Gastroenterology InflammationAutoimmune DiseaseImmunologyGastroenterologyPathology	2000	614
Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped Édouard Louis, Jean–Yves Mary, Gwénola Vernier-Massouille, Gastroenterology InflammationAntimetabolite TherapyAnti-inflammatoryGastroenterologySurgery	2011	589
A controlled double blind study of azathioprine in the management of Crohn's disease. Sally Candy, John Wright, Michele Gerber, Gut	1995	570
Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. William Connell, MA Kamm, J K Ritchie, Gut	1993	513
Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease Laurent Peyrin‐Biroulet, Kiarash Khosrotehrani, Fabrice Carrat, Gastroenterology MedicineNonmelanoma Skin CancersGastroenterologyPathologyDermatology	2011	484

Page 1